Cna Financial Corp Y M Abs Therapeutics, Inc. Transaction History

Cna Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$13.96 - $19.67 $100,372 - $141,427	-7,190 Reduced 30.07%	16,720 $241,000
Q2 2022 Aug 09, 2022	SELL	$8.22 - $15.13 $12,658 - $23,300	-1,540 Reduced 6.05%	23,910 $362,000
Q1 2022 May 10, 2022	BUY	$6.55 - $17.42 $47,291 - $125,772	7,220 Added 39.61%	25,450 $302,000
Q4 2021 Feb 11, 2022	BUY	$15.51 - $29.31 $69,329 - $131,015	4,470 Added 32.49%	18,230 $296,000
Q3 2021 Nov 12, 2021	BUY	$27.47 - $37.31 $12,910 - $17,535	470 Added 3.54%	13,760 $393,000
Q2 2021 Aug 12, 2021	BUY	$25.45 - $37.64 $23,159 - $34,252	910 Added 7.35%	13,290 $449,000
Q1 2021 May 14, 2021	BUY	$29.16 - $51.96 $46,656 - $83,136	1,600 Added 14.84%	12,380 $374,000
Q4 2020 Feb 12, 2021	BUY	$37.86 - $54.26 $33,695 - $48,291	890 Added 9.0%	10,780 $534,000
Q3 2020 Nov 12, 2020	BUY	$35.13 - $43.62 $21,078 - $26,172	600 Added 6.46%	9,890 $380,000
Q2 2020 Aug 13, 2020	BUY	$23.66 - $49.53 $219,801 - $460,133	9,290 New	9,290 $401,000

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.